Identification | Back Directory | [Name]
6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-2-[[3-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]amino]-5,8,11-trimethyl- | [CAS]
1980884-01-2 | [Synonyms]
6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-2-[[3-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]amino]-5,8,11-trimethyl- | [Molecular Formula]
C25H28N6O4S | [MOL File]
1980884-01-2.mol | [Molecular Weight]
508.59 |
Chemical Properties | Back Directory | [Boiling point ]
786.1±70.0 °C(Predicted) | [density ]
1.399±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.44±0.20(Predicted) | [color ]
Off-white to gray |
Hazard Information | Back Directory | [Description]
FMF-02-063-1 inhibits p308 AKT and p473 AKT signaling in isogenic HMEC cell lines where PI3K signaling is driven exclusively by CA-p110-δ under serum starved conditions. FMF-02-063-1 does not inhibit p308 AKT and p473 AKT signaling in isogenic HMEC cell lines where PI3K signaling is driven exclusively by CAp110-α or CA-p110-β. |
|
|